| Data: |
2018 |
| Descripció: |
11 pag. |
| Resum: |
Since they were discovered over a century ago, oncolytic viruses have been expected to produce a cure for cancer. Although results so far have not been promising, the FDA approval of an oncolytic virus (T-VEC) for malignant melanoma in the United States in 2015 has yet opened again the door for this therapy as a potential treatment for cancer. With improved technologies and more knowledge on the matter, scientists have engineered oncolytic viruses and combined them with current therapies. Results obtained in preclinical trials are promising, and some of them are ready to be translated into clinical trials. Oncolytic immunotherapy is particularly promising for glioblastoma, as there are currently no successful treatment available. Moreover, while glioblastoma tumours constantly develop resistance to more classic treatments, no resistance has been observed towards any oncolytic therapy. In this review, oncolytic Herpes Viruses of three subsequent generations that are currently in clinical trials for glioblastoma are examined. |
| Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Llengua: |
Anglès |
| Titulació: |
Ciències Biomèdiques [2501230] |
| Pla d'estudis: |
Grau en Ciències Biomèdiques [832] |
| Document: |
Treball final de grau ; Text |
| Matèria: |
Oncolytic immunotherapy ;
HSV ;
Glioblastoma ;
Combination therapy ;
Oncolytic virus |
visitant ::
identificació
